Although the role of protein kinase C (PKC) has been suggested in agonist-induced bronchial smooth muscle contraction, the PKC isoform(s) involved in this phenomenon is not clear now. In the present study, the effects of three PKC inhibitors, GF1092603X, Gö6976 and rottlerin on acetylcholine (ACh)-induced bronchial smooth muscle contraction were examined to identify the PKC isoform(s) involved in the contraction. Bronchial smooth muscles were pretreated with each PKC inhibitor (10 -6 and 10 -5 M) 30 min before cumulative administration of ACh. In another series of experiments, the effects of PKC inhibitors on the maximal contraction induced by 10 -3 M ACh were determined: the inhibitors were cumulatively administered (10 -8 -10 -5 M) after the AChinduced contraction reached plateau. The ACh-induced bronchial smooth muscle contraction was significantly inhibited by GF109203X (inhibitor of PKCα, β, γ, δ and ε) but not by Gö6976 (PKCδ, β and γ inhibitor) and rottlerin (PKCδ and θ inhibitor).
Introduction
In airway smooth muscle, contraction is mediated by an increase in the concentration of cytosolic Ca 2+ ([Ca 2+ ]i). Ca 2+ binds to calmodulin and subsequently increases myosin light chain kinase (MLCK) activity and phosphorylation of the 20-kDa regulatory myosin light chain (MLC; Gerthoffer and Murphy, 1983) . MLC phosphorylation allows the binding of myosin to actin, which increases actomyosin ATPase activity and causes smooth muscle contraction (Somlyo Correspondence to: Yoshihiko Chiba, Ph.D., Department of Pharmacology, School of Pharmacy, Hoshi University, 2-4-41 Ebara, Shinagawa-ku, Tokyo 142-8501, Japan Phone: 81-3-5498-5787 Fax: 81-3-5498-5787 e-mail: chiba@hoshi.ac.jp and Somlyo, 1994) . The interaction of a physiological agonist with its receptor results in activation of phospholipase C, hydrolysis of the plasma membrane phosphatidylinositol 4,5-bisphosphate, and increased production of inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). Agonists also stimulate Ca 2+ influx through ligand-gated and store-operated Ca 2+ channels, and cause a maintained increase in [Ca 2+ ]i, MLC phosphorylation and smooth muscle contraction (Kanashiro and Khalil, 1998) . However, Hirota et al. (2003) suggest that L-type Ca 2+ channel blockers may not be useful therapeutic agents for the treatment of bronchoconstriction.
In cascade of vascular smooth muscle contraction, the interaction of PKC with its protein substrate may trigger a cascade of protein kinases that ultimately stimulate smooth muscle contraction. PKC phosphorylates PKC-potentiated inhibitory protein for heterotrimeric myosin light chain phosphatase of 17 kDa (CPI-17) which in turn inhibits MLC phosphatase, increases MLC phosphorylation and enhances smooth muscle contraction (Woodsome et al., 2001) . PKC also phosphorylates the actin-binding protein calponin, and thereby reverses its inhibition of actin-activated myosin ATPase, which allows more actin to interact with myosin and increases smooth muscle contraction (Horowitz et al., 1996) . In tracheal smooth muscle, muscarinic receptor stimulation causes an activation of PKC (Yamakage, 1992) . Moreover, it was reported that PKC was involved in ACh-induced bronchial smooth muscle contraction (Sakai et al., 2005) . However, the physiological role of PKC isoforms in receptor agonist-induced bronchial smooth muscle contraction is unknown.
PKC isoforms are classified into three groups. The conventional PKCs (cPKC) α, βI, βII, and γ have four conserved regions (C1-C4) and five variable regions. The C1 region contains binding site for diacylglycerol (DAG) or phorbol esters. The C2 region contains the binding site for Ca 2+ . The C3 and C4 regions contain binding site for ATP, some PKC antagonists and different PKC substrates. The PKC molecule folds to bring the ATP binding site into proximity with the substrate-binding site. The novel PKCs (nPKC) δ, ε, η and θ lack the C2 region and therefore do not require Ca 2+ for activation. The atypical PKCs (aPKC) ξ, λ and ι have only one cysteine-rich zinc finger-like motif and are dependent on phosphatidylserine, but not affected by DAG, phorbol esters or Ca 2+ (Salamanca and Khalil, 2005) .
The purpose of the current study was to identify the PKC isoform(s) involved in acetylcholine (ACh)-induced bronchial smooth muscle contraction. We examined the effects of three PKC inhibitors, GF1092603X, Gö6976 and rottlelin on the ACh-induced bronchial smooth muscle contraction.
Materials and methods

Animals
Male Wistar rats (6 weeks of age, specific pathogen-free, 170-190 g, Charles River Japan, Inc) housed for appropriate time intervals in the animal center of Hoshi University after their arrival. Constant temperature and humidity (22 ± 1°C, 55 ± 10%) were maintained with a fixed 12-hr light-dark cycle and free access to food and water. Experiments were done according to the guiding principles for the care and use of laboratory animals approved by the Animal Care Committee of Hoshi University (Tokyo, Japan).
Functional study
The animals were killed by exsanguination from abdominal aorta under anesthesia with chloral hydrate (400 mg/kg, i.p.). About 4 mm length of the left main bronchus was isolated by the method described previously (Chiba et al., 2001) . The resultant tissue ring preparations were then suspended in a 5-ml organ bath at a resting tension of 1.0 g. The isometrical contraction of the circular smooth muscle was measured with a force-displacement transducer (TB-612T, Nihon Kohden, Japan). The organ bath contained modified Krebs-Henseleit solution with the following composition (mM); NaCl 118.0, KCl 4.7, CaCl2 2.5, MgSO4 1.2, NaHCO3 25.0, KH2PO4 1.2 and glucose 10.0 (pH 7.4). The buffer solution was maintained at 37°C and oxygenated with 95% O2-5% CO2. During an equilibration period in the organ bath, the tissues were washed four times at 15-min intervals and equilibrated slowly to a baseline tension of 1.0 g. After the equilibration period, the concentration-response curve to acetylcholine (ACh; 10 -7 -10 
Immunoblot analysis
To confirm the protein expression of PKCε, Western blot was performed with the homogenates of the main and intrapulmonary bronchi. Briefly, the samples (10 µg of total protein per lane) were subjected to 7.5% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and the proteins were then electrophoretically transferred to a PVDF (polyvinylidene difluoride) membrane. After blocking with 5% skim milk, the PVDF membrane was incubated with primary antibody (monoclonal mouse anti-PKCε, BD Biosciences; 1:2000 dilution). Then the membrane was incubated with horseradish peroxidaseconjugated goat anti-mouse immunoglobulin G (IgG) (1:2500 dilution; Sigma) detected by an enhanced chemiluminescent system (ECL system; Amersham).
RT-PCR analysis
The main and intrapulmonary bronchial tissues were quickly frozen with liquid nitrogen, and these tissues were crushed to pieces by Cryopress TM (CP-100W; Niti-on, Co. Ltd., Japan: 15 sec × 3). Rat brain samples were used as positive control. Total RNA was isolated from each frozen tissue powder by using TRI ® REAGENT (Sigma) and stored at -85°C until use. cDNAs were prepared from the total RNA (1 µg) by reverse transcriptase reaction in a total volume of 50 µL reaction buffer containing 10 mM Tris-HCl, pH 8.3, 50 mM MgCl2, 1 mM dNTP mixture, 1 U/mL RNase inhibitor, 2.5 µM random 9 mers, and 0.25 U/mL avian myeloblastosis virus reverse transcriptase. The reaction mixture was incubated for 5 min at 25°C followed by 60 min at 42°C to initiate the synthesis of the cDNAs. Reverse transcriptase was inactivated at 70°C for 5 min. Then the RT reaction mixture (1 µL) was added by 1 µL of 1 µM forward primer, 1 µL of 1 µM reverse primer, 3 µL of 2 × PCR Master Mix (0.05 units µL -1 Taq DNA polymerase, 4 mM MgCl2 and 0.4 mM of each dNTP; Fermentas Life Science) in a total volume of 20 µL. The PCR primers for rat PKCε used were 5'AGCTTGAAGCCCACAGCCTG3' (sense) and 5'CTTGTGGCCGTTGACCTGATG3' (antisense), which were designed from published sequences (NM_017171). The thermal cycle profile used in the present study was 1) denaturing for 3 min at 95°C, 2) annealing primers for 15 sec at 55°C, and 3) extending the primers for 1 min at 72°C. The PCR amplifications were performed for 35 cycles. The PCR mixtures were subjected to electrophoresis on 2% agarose gel with DNA molecular weight standard marker (100 bp DNA ladder, Takara Bio Inc.) and visualized by etidium bromide staining.
Statistical analyses
Statistical significance of difference was determined by one-way analysis of variance (ANOVA) and Bonferroni/Dunn's post-test. A value of P<0.05 was considered significant. Figure 1 shows the effects of PKC inhibitors on ACh-induced bronchial smooth muscle Figure 3A shows the expression of PKCε mRNAs in rat bronchial smooth muscle, as determined by RT-PCR using total RNA. The expected size of the band for PKCε (465 bp) was clearly detected in rat bronchial smooth muscle. The protein of PKCε in the bronchial smooth muscle was also demonstrated with immunoblot as shown in Fig. 3B .
Results
Effects of PKC inhibitors on ACh-induced bronchial smooth muscle contraction
Expression of PKCε in bronchial smooth muscle
Discussion
Presently, the ACh-induced contraction was inhibited by treatment with GF1092603X (an inhibitor of PKC α, β, γ, δ and ε, but not with Gö6976 (an inhibitor of PKC α, β and γ) and rottlerin (an inhibitor of PKC δ and θ) in rats. Although various isoforms of PKC are expressed in rat bronchial smooth muscle (our personal communication), the mRNA and protein expressions of PKCε were also demonstrated (Fig. 3) . Taken together, our pharmacological studies suggest that PKCε plays an important role in the ACh-induced bronchial smooth muscle contraction.
PKC is a key regulatory enzyme involved in the regulation and cross-talk between signal transduction pathways associated with various cellular functions. PKC is important in regulating smooth muscle contractility in the airways, too. Although the role of each PKC isoform in agonist-induced bronchial smooth muscle contraction is unclear, PKC can phosphorylate a number of key contractile proteins in airway smooth muscle. PKC activation appears to be more involved in the sustained rather than the initial phases of airway smooth muscle contraction (Park and Rasmussen, 1985) .
It has been reported that significant components of PGF2alpha-and endothelin-1-induced contractions of coronary vascular smooth muscle involve Ca 2+ -independent PKCε activation and translocation (Dallas and Khalil, 2003; McNair et al., 2004) . Shirasawa et al. (2003) suggested that PKCε could modulate phenylephrine-induced contraction in mesenteric arteries via calciumindependent pathways. Therefore, in bronchial as well as vascular smooth muscles, PKCε might be involved in agonist-induced smooth muscle contraction.
PKCε lacks the C2 region that contains the binding site for Ca 2+ and therefore does not require Ca 2+ for activation. It is thus possible that PKCε plays important role in the Ca 2+ -independent contraction, i.e., Ca 2+ sensitization, induced by ACh in bronchial smooth muscle.
The activation of PKC by addition of phorbol ester induces a contraction and inhibition of MLC phosphatase (MLCP) of vascular smooth muscles (Itoh et al., 1993; Masuo et al., 1994 ). An inhibitor protein specific for MLCP was isolated from pig aorta smooth muscle extracts and named CPI-17 for PKC-potentiated inhibitory protein for heterotrimeric myosin light chain phosphatase of 17 kDa (Eto et al., 1995) . Expression of CPI-17 is highly restricted to smooth muscle cells (Woodsome et al., 2001) . Phosphorylation of Thr38 in CPI-17 converts it to a potent MLCP inhibitor with an IC50 of ~5 nM (Eto et al., 1995; 1997) . Phospho-CPI-17 enhances both the myosin phosphorylation and contraction of permeabilized arterial smooth muscle (Li et al., 1998) . The expression pattern of CPI-17 among six different smooth muscle tissues (femoral artery, aorta, portal vein, urinary bladder, vas deferens and trachea) correlates with their extent of PKC-induced contraction, implying that CPI-17 is a key to the PKC-mediated agonist-induced smooth muscle contraction (Woodsome et al., 2001 ). In addition, we previously reported that ACh induced phosphorylation of CPI-17 through activation of PKC in rat bronchial smooth muscle (Sakai et al., 2005) . The involvement of novel PKCε has been reported in arterial smooth muscle by using recombinant CPI-17 protein (Kitazawa et al., 1999) . These findings also support that PKCε may activate CPI-17 in bronchial smooth muscle. In addition, PKC is known so far to phosphorylate cytoskeleton and contractile myofilaments. PKC phosphorylates vinculin, a cytoskeletal protein localized at adhesion plaques, thus controlling cell shape and adhesion. A specific link exists between each PKC isoform and one or more specific substrates in airway smooth muscle, and identification of these specific interactions should be further examined.
In conclusion, PKCε might be involved in the ACh-induced bronchial smooth muscle contraction in rats.
